Rubicon Research IPO: GMP, price, important dates and more...
- Krishna Priya
- Oct 8
- 2 min read
The company has set a price band of ₹461 to ₹485 per equity share, with a lot size of 30 shares, translating to a minimum investment of ₹14,550 for retail investors.
IPO Snapshots
Item | Value |
Total Issue Size | ₹1,377.50 Cr |
Fresh Issue | ₹500.00 Cr |
Offer for Sale | ₹877.50 Cr |
Face Value | ₹1 |
Price Band | ₹461 to ₹485 |
Lot Size | 30 |
Minimum Investment | ₹14,550 |
Listing | BSE, NSE |
Opens | October 9, 2025 |
Closes | October 13, 2025 |
Rubicon Research Ltd. is a Mumbai-based pharma formulation producer focused on differentiated generics. With 72 US FDA-approved products and a pipeline of 17 awaiting approval, Rubicon maintains a core presence in the US market, generating over 98% of its revenue from this geography and maintaining strong supply links with major wholesalers. International expansion and in-house R&D drive its value proposition.
Financial Performance (₹ crore)
Period End | Revenue from Ops | PAT |
31 Mar 2025 | 1,284.27 | 134.36 |
31 Mar 2024 | 853.89 | 91.01 |
31 Mar 2023 | 393.52 | (16.89) |
GMP (Grey Market Premium)
As of now, the Grey Market Premium (GMP) for Rubicon Research IPO is ₹92, as of October 8th, 2025. With the cap price of ₹485, the estimated listing price is ₹577, suggesting a potential listing gain of 18.97% per share.
Peer Comparison
Company | CMP (₹) | Mkt Cap (₹ Cr) | P/E | Sales (₹ Cr) | OPM % | PAT 12M (₹ Cr) |
Rubicon Research | - | - | - | 1,284.27 | - | 134.36 |
Sun Pharma.Inds. | 1,631.60 | 391,191.52 | 34.12 | 53,777.09 | 29.69 | 10,397.11 |
Aurobindo Pharma | 1,070.80 | 62,762.46 | 18.51 | 32,024.85 | 20.32 | 3,389.55 |
Zydus Lifesci. | 985.95 | 99,224.71 | 21.31 | 23,607.70 | 29.92 | 4,711.10 |
Strides Pharma | 796.95 | 7,344.38 | 19.60 | 4,630.73 | 17.93 | 353.52 |
Dr Reddy's Labs | 1,234.50 | 102,979.46 | 18.13 | 33,519.90 | 25.42 | 5,742.70 |
Alembic Pharma | 930.65 | 18,271.22 | 30.81 | 6,821.08 | 15.42 | 601.10 |
Lupin | 1,905.60 | 87,046.56 | 23.53 | 23,375.91 | 24.58 | 3,722.18 |
Use of Proceeds
Rubicon Research plans to utilize the IPO proceeds primarily for the prepayment or scheduled repayment of certain outstanding borrowings, amounting to ₹310 crore. The remaining funds are allocated to support inorganic growth, such as unannounced acquisitions, strategic business initiatives, and general corporate purposes.
Disclaimer: This content is for educational purposes only; please conduct your own research and consult with a qualified investment advisor before making any investment decisions.
Want to read more?
Subscribe to finsightsbysquareleague.com to keep reading this exclusive post.